论文部分内容阅读
目的:探讨三维彩色血管能量成像(three-dimensionalcolorpowerangiography,3D-CPA)检测肝癌血管的临床价值。方法:应用3D-CPA检测37例原发性肝癌(PrimaryHepatocarcinomas,HCC)肿瘤血供及血管分布情况,计测肿瘤血管指数(VascularityIndex,VI),术后肿瘤组织切片行CD34单克隆抗体免疫组化染色,计数肿瘤微血管密度(MicrovesselDensity,MVD),对上述结果进行分析。结果:37个肝癌病灶VI为0.2647±0.1249条?cm3,免疫组化计测MVD为(63.31±29.93)?400倍视野,两者比较呈高度线性正相关(r=0.874,P<0.001)。结论:3D-CPA能客观评价肝癌血供,较准确地定量其血管,为临床定性诊断、估测预后及疗效判定提供依据。
Objective: To investigate the clinical value of three-dimensional color contour imaging (3D-CPA) in the detection of hepatic vessels. Methods: The distribution of blood and blood vessels in 37 cases of primary hepatocarcinoma (HCC) were detected by 3D-CPA. The Vascularity Index (VI), the immunohistochemistry of CD34 monoclonal antibody Staining, counting microvessel density (MicrovesselDensity, MVD), the above results were analyzed. Results: The VI of 37 liver cancer patients was 0.2647 ± 0.1249 cm 3, and the MVD was 63.31 ± 29.93 and 400 times as high as that of the 37 eyes. There was a highly linear positive correlation between them (r = 0.874, P <0.001). Conclusion: 3D-CPA can objectively evaluate the blood supply of hepatocellular carcinoma and accurately quantify its blood vessels, which can provide the basis for clinical qualitative diagnosis, prognosis and curative effect evaluation.